Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2016 |
Staging of Upper Tract Urothelial Cancer With Optical Coherence Tomography
This clinical trial studies how well optical coherence tomography works in staging patients
with upper-tract urothelial carcinomas. Staging describes the severity of a person's cancer
based on the size and/or extent (reach) of the original (primary) tumor and whether or not
cancer has spread in the body. It also helps the doctor plan the appropriate treatment.
Optical coherence tomography is a procedure that uses infrared light waves to give
three-dimensional pictures of structures inside tissues and organs. The pictures are made by
a computer linked to the light source. Optical coherence tomography may be effective in
staging patients with upper-tract urothelial carcinomas.
with upper-tract urothelial carcinomas. Staging describes the severity of a person's cancer
based on the size and/or extent (reach) of the original (primary) tumor and whether or not
cancer has spread in the body. It also helps the doctor plan the appropriate treatment.
Optical coherence tomography is a procedure that uses infrared light waves to give
three-dimensional pictures of structures inside tissues and organs. The pictures are made by
a computer linked to the light source. Optical coherence tomography may be effective in
staging patients with upper-tract urothelial carcinomas.
PRIMARY OBJECTIVES:
I. To test the feasibility and imaging ability of optical coherence tomography (OCT) to
stage upper-tract urothelial carcinomas (UTUC).
OUTLINE:
Patients undergo optical coherence tomography over 10-15 minutes.
After completion of study, patients are followed up at 3 months.
I. To test the feasibility and imaging ability of optical coherence tomography (OCT) to
stage upper-tract urothelial carcinomas (UTUC).
OUTLINE:
Patients undergo optical coherence tomography over 10-15 minutes.
After completion of study, patients are followed up at 3 months.
Inclusion Criteria:
- Patients must have radiographic evidence of upper tract urothelial cancer by computed
tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in
order to undergo this procedure
- Patient who will undergo standard of care clinical staging for UTUC
- Patient ability to read and comprehend the informed consent document
Exclusion Criteria:
- Patient who has a contraindication to endoscopy
- Patient who is pregnant
We found this trial at
1
site
11100 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.844.8797
Principal Investigator: Donald R Bodner, MD
Phone: 216-844-5503
Case Comprehensive Cancer Center The Case Comprehensive Cancer Center (Case CCC) based at Case Western...
Click here to add this to my saved trials
